[go: up one dir, main page]

SV2017005417A - Composición farmacéutica solida que comprende amlodipino y losartán - Google Patents

Composición farmacéutica solida que comprende amlodipino y losartán

Info

Publication number
SV2017005417A
SV2017005417A SV2017005417A SV2017005417A SV2017005417A SV 2017005417 A SV2017005417 A SV 2017005417A SV 2017005417 A SV2017005417 A SV 2017005417A SV 2017005417 A SV2017005417 A SV 2017005417A SV 2017005417 A SV2017005417 A SV 2017005417A
Authority
SV
El Salvador
Prior art keywords
amlodipino
pharmaceutical composition
losartán
composition including
solid pharmaceutical
Prior art date
Application number
SV2017005417A
Other languages
English (en)
Inventor
Leedong Roh
Ho Taek Im
Young Su Yoon
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SV2017005417A publication Critical patent/SV2017005417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UNA COMPOSICIÓN FARMACÉUTICA PARA LA PREVENCIÓN O EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES QUE CONTIENEN LOSARTÁN O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO; AMLODIPINO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO; UN DESINTEGRANTE; Y UN AGENTE DE REVESTIMIENTO. LA COMPOSICIÓN DE LA PRESENTE INVENCIÓN, LA CUAL TIENE LA MEJOR COMBINACIÓN Y RELACIÓN ÓPTIMA DE UN DESINTEGRANTE A UN AGENTE DE REVESTIMIENTO, MUESTRA RESISTENCIA SUFICIENTE Y ALTAS TASAS DE DISOLUCIÓN BAJO VARIOS AMBIENTES DE PH, Y DE ESTA MANERA, ES ÚTIL PARA LA PREPARACIÓN DE UNA FORMULACIÓN SÓLIDA EXCELENTE QUE MUESTRA EFICIENCIA DE SUMINISTRO DE FÁRMACO .Y ESTABILIDAD DE ALMACENAMIENTO MEJORADAS
SV2017005417A 2014-09-30 2017-03-29 Composición farmacéutica solida que comprende amlodipino y losartán SV2017005417A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140131834 2014-09-30

Publications (1)

Publication Number Publication Date
SV2017005417A true SV2017005417A (es) 2017-10-13

Family

ID=55630854

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005417A SV2017005417A (es) 2014-09-30 2017-03-29 Composición farmacéutica solida que comprende amlodipino y losartán

Country Status (20)

Country Link
US (1) US10034862B2 (es)
JP (1) JP2017530137A (es)
KR (1) KR102369607B1 (es)
CN (2) CN107018650B (es)
AR (1) AR101860A1 (es)
CO (1) CO2017003913A2 (es)
CR (1) CR20170125A (es)
DO (1) DOP2017000084A (es)
EC (1) ECSP17022124A (es)
JO (1) JO3435B1 (es)
MX (1) MX377103B (es)
MY (1) MY188302A (es)
PH (1) PH12017500536A1 (es)
RU (1) RU2698703C2 (es)
SG (1) SG11201702364VA (es)
SV (1) SV2017005417A (es)
TW (1) TWI681773B (es)
UY (1) UY36331A (es)
WO (1) WO2016052866A1 (es)
ZA (1) ZA201703015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
CR20190265A (es) * 2016-11-15 2019-08-22 Hanmi Pharm Ind Co Ltd Preparación de un complejo farmacéutico que comprende amlodipina, losartán y rosuvastatina
CN115666564B (zh) * 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
AU685898B2 (en) 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
WO2010026470A1 (en) 2008-09-04 2010-03-11 Aurobindo Pharma Limited Stable dosage forms of antihypertensive agents
SG173044A1 (en) * 2009-01-23 2011-08-29 Hanmi Holdings Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
KR101888692B1 (ko) * 2011-03-25 2018-09-20 한미사이언스 주식회사 로자탄, 암로디핀 및 히드로클로로티아지드를 함유하는 고정 조합 투여 제형 조성물
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물

Also Published As

Publication number Publication date
CN107018650A (zh) 2017-08-04
DOP2017000084A (es) 2017-07-31
RU2017114993A3 (es) 2019-04-05
JP2017530137A (ja) 2017-10-12
MX377103B (es) 2025-03-07
US10034862B2 (en) 2018-07-31
US20170326110A1 (en) 2017-11-16
UY36331A (es) 2016-04-29
AR101860A1 (es) 2017-01-18
WO2016052866A1 (en) 2016-04-07
RU2698703C2 (ru) 2019-08-29
CN107018650B (zh) 2021-02-02
CR20170125A (es) 2017-07-06
CN112716951A (zh) 2021-04-30
KR102369607B1 (ko) 2022-03-03
TW201617075A (zh) 2016-05-16
KR20160038734A (ko) 2016-04-07
PH12017500536A1 (en) 2017-08-07
RU2017114993A (ru) 2018-11-05
ECSP17022124A (es) 2018-05-31
MY188302A (en) 2021-11-26
ZA201703015B (en) 2019-07-31
TWI681773B (zh) 2020-01-11
CO2017003913A2 (es) 2017-04-28
MX2017004032A (es) 2017-07-07
SG11201702364VA (en) 2017-05-30
JO3435B1 (ar) 2019-10-20

Similar Documents

Publication Publication Date Title
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX383227B (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
AR093705A1 (es) Depsipeptido y sus usos
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
SV2017005417A (es) Composición farmacéutica solida que comprende amlodipino y losartán
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CL2017000026A1 (es) Formas de dosificación farmacéutica
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201792676A1 (ru) Ингибиторы jak1
TN2016000479A1 (en) Nitisinone dosing regimens for the treatment of alkaptonuria.
AR106203A1 (es) Terapia combinada y régimen de tratamiento del hcv
CU20160170A7 (es) Derivados de carboxamida
MX393741B (es) Comprimido recubierto con pelicula para el tratamiento del dolor agudo.
AR104570A1 (es) Métodos de tratamiento de una enfermedad neurodegenerativa
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид